Eli Lilly and Company (NYSE:LLY) Stock Position Increased by Brooklyn Investment Group

Brooklyn Investment Group boosted its position in Eli Lilly and Company (NYSE:LLY) by 7.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,639 shares of the company’s stock after purchasing an additional 404 shares during the quarter. Eli Lilly and Company comprises about 1.6% of Brooklyn Investment Group’s holdings, making the stock its 8th largest position. Brooklyn Investment Group’s holdings in Eli Lilly and Company were worth $4,996,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Jacobs Levy Equity Management Inc. increased its stake in Eli Lilly and Company by 357.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 11,074 shares of the company’s stock valued at $8,615,000 after purchasing an additional 8,651 shares during the last quarter. Dynasty Wealth Management LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth about $698,000. Ancora Advisors LLC boosted its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Ancora Advisors LLC now owns 6,763 shares of the company’s stock worth $5,261,000 after acquiring an additional 52 shares during the last quarter. Creekmur Asset Management LLC grew its holdings in Eli Lilly and Company by 69.5% in the first quarter. Creekmur Asset Management LLC now owns 222 shares of the company’s stock valued at $173,000 after purchasing an additional 91 shares during the period. Finally, Tidal Investments LLC increased its position in Eli Lilly and Company by 24.4% during the first quarter. Tidal Investments LLC now owns 38,519 shares of the company’s stock worth $29,966,000 after purchasing an additional 7,559 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Bank of America decreased their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $755.00 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market capitalization of $716.73 billion, a price-to-earnings ratio of 81.62, a PEG ratio of 2.83 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53. The company’s 50-day simple moving average is $861.63 and its 200-day simple moving average is $870.20.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 EPS. Equities analysts anticipate that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.